Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders

The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing...

Full description

Saved in:
Bibliographic Details
Main Authors ZALESKA, MARGARET M, PANGALOS, MENELAS N, HOLZBAUR-HOWLAND, ERIKA L.F, HOWLAND, DAVID S, WALLACE, KAREN, KARIM, RIYEZ, WEBER, NICHOLAS, KWAK, SEUNG POON, TCHISTIAKOVA, LIOUDMILA, KELLEY, PAMELA, WALSH, FRANK S, TAN, XIANG-YANG
Format Patent
LanguageEnglish
French
German
Published 18.01.2012
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.
Bibliography:Application Number: EP20110161564